IP Library Granted Patent US 10,201,517
Granted Patent B2
US 10,201,517 · App. 15/220,501 · Granted Feb 12, 2019

Brimonidine gel compositions and methods of use

Inventors: Jean-Christophe Buge (Nice, FR); Karine Nadau Fourcade (Villeneuve Loubet, FR); Cyril Meunier (St. Raphael, FR)
Assignee: Galderma Laboratories, L.P.
A61K31/235A61K8/29A61K8/34A61K8/345A61K8/37A61K8/4946A61K8/8147A61K8/86A61K9/0014A61K9/06A61K31/498A61K45/06A61K47/02A61K47/10A61K47/14A61K47/32A61K47/34A61Q19/00A61Q19/08A61K2800/594A61K2800/5922
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,517
App. No.
15/220,501
Granted
Feb 12, 2019
Kind
B2
Abstract

Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.

Claims (30)

1. A topical gel composition, comprising:

0.05% to 5% (w/w) brimonidine or brimonidine tartrate;

0.1% to 0.20% (w/w) methylparaben;

0.3% to 0.4% (w/w) phenoxyethanol;

0.80% to 1.50% (w/w) carbomer;

9.0% to 13.0% (w/w) total polyol,

wherein the topical gel composition has a pH of 4.5 to 7.5, and

wherein when the concentration of methylparaben is greater than 0.15% (w/w), the concentration of carbomer is less than 1.25% (w/w).

2. The topical gel composition of claim 1 , wherein the total polyol comprises about 4.5% to 6.5% (w/w) a first polyol, and one or more additional polyols.

3. The topical gel composition of claim 1 , wherein the carbomer is selected from the group consisting of carbomer 934P, carbomer 974P, and carbomer 980.

4. The topical gel composition of claim 1 , comprising:

0.1% to 0.6% (w/w) brimonidine tartrate;

0.1% to 0.15% (w/w) methylparaben;

0.3% to 0.4% (w/w) phenoxyethanol;

0.80% to 1.50% (w/w) carbomer;

4.5% to 6.5% (w/w) propylene glycol;

4.5% to 6.5% (w/w) glycerol; and

purified water

wherein the pH of the topical gel composition is adjusted to 5.0 to 6.5 by an adequate amount of sodium hydroxide aqueous solution.

5. The topical gel composition of claim 4 , comprising greater than 0.3% (w/w) phenoxyethanol.

6. The topical gel composition of claim 5 , further comprising 0.04% to 0.08% (w/w) water dispersible form of titanium dioxide.

7. A topical gel composition, comprising:

0.1% to 0.6% (w/w) brimonidine tartrate;

0.1% to 0.15% (w/w) methylparaben;

0.3% to 0.4% (w/w) phenoxyethanol;

0.80% to 1.50% (w/w) carbomer;

4.5% to 6.5% (w/w) propylene glycol;

4.5% to 6.5% (w/w) glycerol;

0.04% to 0.08% (w/w) water dispersible form of titanium dioxide; and purified water

wherein the pH of the topical gel composition is 5.0 to 6.5.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Mar 10, 2022
From: NESTLÉ SKIN HEALTH SA; GALDERMA HOLDINGS SA
To: GALDERMA HOLDING SA
Reel/Frame 060044/0523 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: GALDERMA LABORATORIES, INC.; GALDERMA LABORATORIES, L.P.
To: NESTLÉ SKIN HEALTH SA
Reel/Frame 058461/0396 →
Priority Claims (1)
FR 10 58612 · Oct 21, 2010 · national
Continuity (4)
Continuation 13824635
Continuation 13158987 · Jun 13, 2011
Provisional Application 61405388 · Oct 21, 2010
Related Publication 20160331715A1 · Nov 17, 2016